Best Compounded Semaglutide Alternatives in 2026: Your Real, Legal Options

The short answer

The best compounded semaglutide alternatives in 2026 are the FDA-approved GLP-1 medications themselves — and they cost far less than they used to. During the shortage, compounded versions were a lower-cost workaround. That shortage is over. So the approved medicines are the standard option again, and prices have dropped hard. Your strongest, most established replacements today are:

• FDA-approved semaglutide — Wegovy (injection) or oral Wegovy (a pill)
• FDA-approved tirzepatide — Zepbound (injection), often the strongest option for weight loss
• A different FDA-approved GLP-1 pill — Foundayo (orforglipron), starting around $149/month
• A patient-specific compounded formula — but only when an FDA-approved drug can’t meet a documented medical need. Price alone is not that lane.

Which one is right depends on three things: your budget, whether you want a pill or a shot, and your insurance. Through manufacturer self-pay programs, selected doses now run roughly $149–$449 a month before any membership or visit fees — down from over $1,000 a year ago.

This is not for you if you’re hoping to keep buying cheap “copycat” semaglutide from an online seller. That door is mostly closed, and the sellers still doing it are exactly who the FDA and FTC are cracking down on right now. We’ll show you the safer path instead — and it’s closer in price than you’d expect.

Your situation, your starting point

Most people landing here are switching for one specific reason. Find yours, and you’ll know where to look first.

Why is compounded semaglutide suddenly so hard to get?

Compounded semaglutide became widely available because of a national shortage. The FDA declared the semaglutide shortage resolved on February 21, 2025, and the temporary rules that let pharmacies make copies were wound down in spring 2025. Since then, making a near-copy of semaglutide is no longer permitted for routine use — and in 2026 the FDA proposed to block large-scale compounding of it for good.

Compounded drugs are custom-mixed by a pharmacy. They are not FDA-approved, which means the FDA does not check them for safety, effectiveness, or quality before they’re sold (FDA). During the shortage, two kinds of pharmacies could make copies of semaglutide: 503A pharmacies (state-licensed pharmacies that fill one prescription at a time) and 503B outsourcing facilities (larger operations that make medications in bulk).

Here’s the timeline, plain and simple:

• December 2024: FDA declared the tirzepatide shortage resolved.
• February 21, 2025: FDA declared the semaglutide shortage resolved (FDA).
• Spring 2025: The FDA’s shortage-based enforcement discretion ended — April 22, 2025 for 503A pharmacies, May 22, 2025 for 503B facilities. After those dates, compounding products that are “essentially a copy” of semaglutide was no longer permitted.
• 2026: The FDA proposed to remove semaglutide, tirzepatide, and liraglutide from the list of bulk ingredients that large outsourcing facilities may compound from. A public comment period runs through June 29, 2026 (FDA).

So if your telehealth provider sent you a discontinuation notice, or you’ve seen headlines about a “ban,” this is what’s behind it. The legal basis for cheap, mass-market compounded semaglutide went away when the shortage ended.

One important nuance: this does not mean every compounded prescription is illegal forever. The FDA itself says a compounded drug “might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available.” A licensed clinician can still order one in those narrow situations. But the days of ordering a cheap copy online “just because it’s cheaper” are over. See our full guide: Is compounded GLP-1 still available in 2026?

What are the best compounded semaglutide alternatives by route?

The FDA-approved replacement routes are Wegovy and oral Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron) for weight management. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and used off-label for weight. As of June 16, 2026, manufacturer self-pay prices for selected doses run roughly $149–$449 a month before membership or visit fees.

The RX Index alternative comparison

Last verified June 16, 2026. Cash prices change month to month — we re-check these on the 1st. Eligibility always requires a licensed clinician. Compounded medications are not FDA-approved finished drugs.

A quick translation of that table: if you want to stay on semaglutide, oral Wegovy or the Wegovy shot is your closest match. If you just want something that works and you’re open to a different medicine, Zepbound (shot) has the strongest head-to-head data of the current options, and Foundayo (pill) is often the cheapest way in the door. Compare real pricing details in our compounded vs. brand-name GLP-1 guide.

Compounded vs. FDA-approved semaglutide: what actually changed?

Compounded semaglutide was mixed by pharmacies as a lower-cost option during the shortage. FDA-approved Wegovy and Ozempic are the manufacturer products that pass FDA review for quality, dosing, and labeling before they’re sold. Now that the shortage is over, the FDA-approved products are the standard option again — and unlike compounded versions, they’re regulated from start to finish.

We can’t tell you compounded products are “the same as” the FDA-approved drugs — and you should be suspicious of any website that does. The FDA has been sending warning letters to companies that made exactly that claim. The honest framing:

• FDA-approved drugs are reviewed by the FDA for safety, effectiveness, and quality before they’re sold, and they come with standardized labeling and dosing.
• Compounded drugs skip that review. They can be appropriate in specific situations, but they aren’t checked the same way, and quality can vary from pharmacy to pharmacy (FDA).

The big shift in 2026 is that the FDA-approved versions got dramatically cheaper at the very moment compounded access tightened. So the gap that used to push people toward copies — price — has shrunk a lot. For a deeper breakdown see our guide on compounded GLP-1 alternatives in 2026.

What’s the cheapest legal alternative to compounded semaglutide without insurance?

The lowest entry prices among FDA-approved options right now are oral Wegovy and Foundayo, both starting around $149 a month, plus new-patient intro pricing on Wegovy (around $199/month for the first two months). With a commercial insurance savings card, some people pay as little as $25/month, and eligible Medicare Part D patients can get certain GLP-1s for a $50/month copay through the Medicare GLP-1 Bridge starting July 1, 2026 (CMS).

Here’s the part nobody told you when you were paying for compounded: the cash price of the real thing fell off a cliff in late 2025. The two manufacturers got into a price war — Novo Nordisk cut Wegovy and Ozempic cash prices to about $349/month (CNBC), Eli Lilly cut Zepbound to $299–$449 through its Self Pay Journey Program, and the FDA approved two GLP-1 pills with entry prices around $149/month.

The lowest legitimate starting prices today:

Watch the full cost, not just the sticker. Add up: the medication, any membership fee, the first visit, follow-up visits, lab work, shipping, whether you’re locked into a multi-month plan, and how hard it is to cancel.

Two more ways to pay less, legally:

• Insurance + prior authorization. Many plans don’t cover weight-loss drugs by default, but some do with paperwork. A program with insurance support can do that legwork for you. See our guide to getting semaglutide covered.
• The Medicare GLP-1 Bridge. Starting July 1, 2026 and running through December 31, 2027, eligible Medicare Part D members can get certain GLP-1s for a $50/month copay when prescribed for weight management and approved through prior authorization. That $50 doesn’t count toward your Part D out-of-pocket totals (CMS). For a deeper breakdown, see our GLP-1 cost guide.

See real, dose-by-dose pricing breakdowns in our guides for cheapest Wegovy without insurance, cheapest Zepbound without insurance, and Foundayo cost without insurance.

What if I want a pill instead of a shot?

There are now two FDA-approved GLP-1 pills for weight management: oral Wegovy (semaglutide tablets, approved December 2025) and Foundayo (orforglipron, approved April 2026). Foundayo can be taken any time of day with no food or water restrictions; oral Wegovy must be taken on an empty stomach in the morning. Rybelsus is an older oral semaglutide, but it’s approved for type 2 diabetes, not weight loss.

A lot of people went the compounded route for a needle-free option — drops, lozenges, or tablets. Good news: you no longer have to go outside the FDA-approved world to get a pill.

• Foundayo (orforglipron) is a once-daily pill. No food or water rules — you can take it any time. In Eli Lilly’s main trial (ATTAIN-1), people on the highest dose who stayed on treatment lost about 12% of their body weight on average. It’s the newest option and tends to have the lowest entry price.
• Oral Wegovy is semaglutide in tablet form. It works, but it’s fussier to take: empty stomach, morning only, small sip of water, then wait 30 minutes before eating or drinking.

One honest safety note on the pills (and all GLP-1s): like the rest of this class, they carry a warning about the risk of thyroid tumors, including thyroid cancer, based on animal studies. They’re not for people with a personal or family history of medullary thyroid cancer or a condition called MEN2. This is a real conversation to have with your clinician — not a reason to panic, but a reason to be honest about your history.

Is compounded tirzepatide a better alternative than compounded semaglutide?

FDA-approved tirzepatide — sold as Zepbound — is often a stronger choice than semaglutide for weight loss, and it’s a legitimate, regulated option. But compounded tirzepatide has the same core problem as compounded semaglutide: it’s not an FDA-approved finished drug, and the shortage that allowed it ended in December 2024.

Tirzepatide works on two gut hormones instead of one, and in head-to-head trial data it has produced more weight loss on average than semaglutide. So switching “up” to tirzepatide is a reasonable thing to ask about. Just don’t switch into a compounded version thinking you’ve found a loophole. The FDA’s warnings about compounded GLP-1s apply to compounded tirzepatide just as much as to semaglutide. The smart move, if a clinician agrees it fits you: FDA-approved Zepbound, where the trial evidence and the quality oversight actually apply. See how to make that switch in our guide: How to switch from compounded semaglutide to Zepbound.

Is oral Wegovy the same as the compounded “semaglutide drops” I’ve seen?

No. Oral Wegovy is an FDA-approved semaglutide tablet. Compounded oral drops, sprays, or lozenges are pharmacy-mixed products that are not FDA-approved finished drugs. The FDA has specifically warned companies against marketing compounded products as if they were the same as approved medications.

If a website is selling “semaglutide drops” or “sublingual semaglutide” and making it sound identical to Wegovy or Ozempic, that’s a red flag — not a feature. In early 2026, the FDA issued warning letters to 30 telehealth companies for exactly this kind of marketing: claims that implied their compounded products were the same as FDA-approved drugs, and labeling that hid who actually made the product (FDA). So: oral Wegovy and Foundayo are FDA-approved pills. Compounded drops and lozenges are a different, non-FDA-approved category. Don’t let a slick website blur the line for you.

What are the real risks of switching — and the red flags to avoid?

The biggest risks aren’t only medical side effects. They include choosing an unstable or illegal source, buying a fake or contaminated product, dosing yourself wrong, and getting trapped in a subscription with hidden fees. Both the FDA and the FTC have taken action against companies in this space.

Dosing mistakes happen with compounded injections. The FDA has received reports of patients measuring and giving themselves the wrong dose — sometimes far more than intended — often because they weren’t used to drawing medicine from a vial or got confused between milligrams, milliliters, and “units.” Reported problems have ranged from nausea and vomiting to issues serious enough to need medical attention (FDA).

The adverse-event reports are adding up. As of May 31, 2026, the FDA had received 990 reports of adverse events tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The FDA notes these are likely undercounted — and also that it isn’t always possible to tell whether the drug itself caused a given event (FDA). Read that honestly: it’s a caution flag about an unregulated supply, not proof that every dose causes harm.

Some “semaglutide” isn’t the approved ingredient at all. The FDA has warned that certain compounded products use salt forms — semaglutide sodium or semaglutide acetate — which are different active ingredients from what’s in the approved drugs. The FDA has said it doesn’t have information showing these salts work the same way (FDA).

Counterfeits are circulating. The FDA has found fake versions of these drugs in the U.S. supply, sometimes with the wrong ingredient, the wrong dose, or no active drug at all. Products marketed “for research use only” but sold for people to inject are a serious danger (FDA).

Hidden fees and fake reviews are a known scam pattern. In December 2025, the FTC finalized an order against a telehealth company called NextMed. The FTC said the company advertised low prices that didn’t include the actual drug, labs, or doctor visits; locked people into memberships with termination fees; and posted fake reviews from people who weren’t even customers. The company paid $150,000 in refunds (FTC).

Use this checklist before you pay anyone — FDA-approved or compounded:

• Is this an FDA-approved medication, or a compounded product? (Make them tell you plainly.)
• Exactly what medication and formulation will I get?
• Which pharmacy fills it, and is it licensed in my state?
• What’s the first-month price — and the refill price after that?
• Are labs, visits, and shipping included, or extra?
• Am I locked into a contract? How, exactly, do I cancel?
• Who do I contact about side effects or dosing?

If a provider won’t answer those clearly, that is your answer.

How do I switch off compounded semaglutide without losing my progress?

Don’t panic-buy the first replacement you see. The safer path is to gather your current prescription details, decide what matters most to you, compare your routes, verify the provider’s terms, and have a licensed clinician guide the transition and dose. Here’s the step-by-step plan:

1. Write down where you are. Your current medication, your dose, your refill date, and any side effects you’ve had.
2. Pick your one non-negotiable. FDA-approved only? Lowest possible price? No needles? Insurance help? Naming it makes the rest of the decision easy.
3. Match it to a route. Want FDA-approved certainty → oral Wegovy, Wegovy, Zepbound, or Foundayo, through a clinician, the manufacturer’s program, or a telehealth provider. Want insurance help → a program with prior-authorization support.
4. Verify before you pay. Run the red-flag checklist above.
5. Let a clinician handle the dose. Switching medicines or doses is a medical decision. Bring your notes from step 1 to a licensed provider and let them guide the transition safely.

For route-specific guidance, see our guides on switching from compounded to brand GLP-1 and how to switch from compounded semaglutide to Zepbound.

Should I use a telehealth provider, and which one?

A telehealth provider makes sense if you want a guided program — a clinician to prescribe, help with dosing and questions, and in some cases help with insurance — instead of piecing it together yourself. For people replacing compounded semaglutide who want FDA-approved medication and insurance help, Ro is our top pick to check first.

Ro — best first check for FDA-approved medication and insurance help

The punchline: If your reason for leaving compounded semaglutide is wanting FDA-approved medication, a guided program, or help getting insurance to cover it, Ro is the cleanest place to start.

Ro is a telehealth program that prescribes FDA-approved GLP-1 options — including the Wegovy pill, Wegovy pen, Foundayo pill, and Zepbound KwikPen — where they’re clinically appropriate. The Ro Body membership is $39 for the first month, then as low as $74/month if you prepay for a year (monthly plans cost more), and the medication is charged on top (Ro). Ro states its medication prices match LillyDirect, NovoCare, and TrumpRx, and it offers a dedicated insurance concierge plus a free GLP-1 Insurance Coverage Checker (Ro). Full pricing details in our Ro GLP-1 cost guide.

Best for: people who want FDA-approved options, a clinician guiding the process, and help with insurance or prior authorization.

The honest tradeoff: Ro is not the cheapest path if you already have a prescriber and just want to pay cash for the brand. If that’s you, buying directly from LillyDirect or NovoCare will usually cost less, because you skip the membership. But that membership is the whole point if you want guidance and insurance help — and for a lot of people leaving compounded, it’s worth it.

Ro vs. buying direct: which route should you use?

If you’re insured or insurance-curious, start with Ro’s free checker. If you’re paying cash and already have a prescriber, go direct. If you like shopping individual visits, compare Sesame.

What about the narrow case where compounded is still allowed?

The FDA says a compounded drug may be appropriate when an FDA-approved drug can’t meet a patient’s documented medical need, or when the FDA-approved drug isn’t commercially available. In those cases a licensed clinician can prescribe a patient-specific compounded medication, filled by a state-licensed pharmacy. It is not a workaround for getting a cheaper copy.

If a commercial GLP-1 genuinely won’t work for you — say you react to one of the inactive ingredients, or you need a dose that isn’t sold — a clinician can still order a patient-specific compounded medication (FDA). Two things matter most: the prescription comes from a licensed clinician who knows your history, and it’s filled by a state-licensed pharmacy you can verify (check your state board of pharmacy).

But if you’re here just because compounded was cheaper, this lane isn’t for you — and with FDA-approved prices now starting around $149/month, the savings argument is a lot weaker than it was.

How we chose these alternatives

We ranked alternatives by legal status first, then current verified cost, route, and who each option fits best — not by what pays us. Here’s our scoring, in order of weight:

1. Legal and regulatory standing (highest) — you’re worried about safety and stability, so this comes first.
2. Price transparency — the real, all-in cost, not a sticker that hides fees.
3. Care model — GLP-1s need a clinician’s oversight.
4. Access — state availability, insurance options, pharmacy route.
5. Pill vs. shot fit — “alternative” often means “a format I can live with.”
6. Billing and cancellation fairness — because the FTC’s NextMed case shows this is a genuine buyer risk.

What gets a provider disqualified: no real prescription process; products sold “for research use only”; claims that compounded products are the same as FDA-approved drugs; no clear pharmacy; no clear refill price; fake or manipulated reviews; promises of guaranteed weight loss.

For a broader look at how we evaluate providers, see our brand-name GLP-1 telehealth provider guide.

What we actually verified

Everything below was checked against primary sources on June 16, 2026:

• FDA dates for the semaglutide and tirzepatide shortage resolutions, and the end of the compounding enforcement-discretion periods.
• The FDA’s 2026 proposal to restrict large-scale (503B) bulk compounding, with comments open through June 29, 2026.
• The FDA’s warning letters to 30 telehealth companies and its safety concerns (salt forms, dosing errors, counterfeits) and current adverse-event counts (990 semaglutide / 730+ tirzepatide as of May 31, 2026).
• The FTC’s final order against NextMed (December 2025).
• Foundayo’s FDA approval and entry pricing; current Wegovy and Zepbound self-pay prices.
• The Medicare GLP-1 Bridge ($50 copay, July 1, 2026–December 31, 2027) from CMS.
• Ro’s current membership pricing, medication list, and insurance checker, from Ro’s site.

Prices and policies in this space change monthly. We re-verify on the 1st and update the date at the top.

What real reviews tend to reveal

When we read through public reviews of GLP-1 telehealth programs, the same themes come up again and again. (Note: some companies pay for or solicit testimonials, so look for patterns, not single glowing quotes.)

• How fast the provider answers questions.
• Whether the monthly price was clear, or whether surprise costs showed up.
• How smooth — or painful — cancellation was.
• Whether shipping was reliable and the medication arrived properly (injectable GLP-1s need refrigeration; the FDA has warned about compounded products arriving warm).
• Whether the intro price jumped at refill.

None of that is about whether the medicine works — that’s between you and your clinician. It’s about whether the service treats you straight. Use the red-flag checklist above to screen for it.

Frequently asked questions

Is compounded semaglutide still legal in 2026?

In narrow, patient-specific cases, yes — but the broad shortage-era market is gone. The FDA declared the semaglutide shortage resolved in February 2025, and copying it is no longer permitted for routine use. The FDA says a compounded drug may still be appropriate when an FDA-approved drug can’t meet a patient’s documented medical need, or isn’t commercially available.

What is the closest FDA-approved alternative to compounded semaglutide?

For semaglutide specifically, oral Wegovy (a pill) or the Wegovy injection is the closest FDA-approved match — the same molecule, now regulated, at cash prices around $149–$349/month depending on form. For a different but often stronger option, Zepbound (tirzepatide) is also FDA-approved.

Is there a cheaper alternative to Wegovy?

Foundayo (orforglipron), an FDA-approved GLP-1 pill, starts around $149/month and can be about $25/month with a commercial insurance savings card. Compare all current options in the table above, and remember to add up the full cost, not just the medication price.

Can I still get compounded tirzepatide instead?

The same rules apply. The tirzepatide shortage ended in December 2024, so broad compounding of it is no longer permitted. If you want tirzepatide’s benefits, FDA-approved Zepbound is the route that’s both legal and regulated.

Are compounded semaglutide drops or lozenges FDA-approved?

No. FDA-approved pills such as oral Wegovy and Foundayo and pharmacy-compounded drops or lozenges are different categories. Compounded products are not FDA-approved, and the FDA has warned companies against marketing them as if they were the same as approved drugs.

Is compounded semaglutide safe?

It sits outside FDA review for safety, effectiveness, and quality. The FDA has received hundreds of adverse-event reports involving compounded semaglutide — some possibly tied to dosing errors, doses beyond the approved labeling, unapproved salt forms, or counterfeits — though it notes it can’t always confirm the drug caused a given event. If a clinician decides a patient-specific compound is right for you, use a verified, state-licensed pharmacy.

Can I switch from compounded semaglutide to Wegovy, Foundayo, or Zepbound?

Often, yes — but that’s a clinician’s call. Bring your current medication, dose history, and any side effects to a licensed provider so they can guide the switch and the right starting dose safely. See our switching guide for what to expect.

What should I avoid when shopping for alternatives?

Avoid sellers with no real prescription process, products labeled “for research only,” claims that compounded drugs are identical to FDA-approved ones, unclear refill prices, hard-to-cancel subscriptions, and fake reviews. The FDA and FTC have both taken action against companies doing these things — treat them as serious red flags.

Sources

1. FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (adverse-event counts as of May 31, 2026; salt forms; dosing errors; counterfeits; shipping/storage): fda.gov
2. FDA — FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s: fda.gov
3. FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage resolution and enforcement dates): fda.gov
4. FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (comment period through June 29, 2026): fda.gov
5. FDA — Understanding the Risks of Compounded Drugs: fda.gov
6. CMS — Medicare GLP-1 Bridge ($50 copay; July 1, 2026–December 31, 2027; outside Part D): cms.gov
7. FTC — FTC Approves Final Order against Telehealth Provider NextMed (Dec 3, 2025): ftc.gov
8. Eli Lilly — Foundayo (orforglipron) approval and pricing; ATTAIN-1 trial; Zepbound Self Pay Journey Program terms: lilly.com
9. CNBC / FiercePharma — Wegovy, Ozempic, and Zepbound cash-price changes (late 2025).
10. Ro — weight-loss program pricing, medication list, and GLP-1 Insurance Coverage Checker: ro.co/weight-loss/pricing

The RX Index is an independent guide. We are not the manufacturer or pharmacy for any medication discussed, and we are not a substitute for your clinician. Verify all prices and program terms on the provider’s site before purchasing.